Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 14:20 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Publishes Comprehensive Voice of the Patient Report Following Externally Led PFDD Meeting with the FDA

The FSR Voice of the Patient report outlines a clear path forward for drug developers, researchers, clinicians, and regulators for sarcoidosis.
December 18, 2025 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo announces it has begun a rolling submission of its BLA to the FDA for , an investigational gene therapy for adults with Fabry disease
December 18, 2025 08:00 ET | Source: Nutriband Inc.

Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Quanta LOI
December 18, 2025 07:00 ET | Source: Nutriband Inc.

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Fentanyl designation Response
December 16, 2025 12:18 ET | Source: Equity Insider

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
December 16, 2025 08:45 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and...
December 15, 2025 08:30 ET | Source: NetraMark Holdings Inc.

NetraMark Achieves Major FDA Milestone

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is...
December 12, 2025 10:31 ET | Source: Equity Insider

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal...
December 12, 2025 08:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics...
December 11, 2025 08:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials